Tandem Diabetes Care Stock Price Target and Analyst Ratings (NASDAQ:TNDM)

Analyst Price Target for TNDM

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

^$115.92

▲ +24.76% Upside Potential

This price target is based on 13 analysts offering 12 month price targets for Tandem Diabetes Care in the last 3 months. The average price target is $115.92, with a high forecast of $150.00 and a low forecast of $75.00. The average price target represents a 24.76% upside from the last price of $92.92.

Buy

The current consensus among 13 investment analysts is to buy stock in Tandem Diabetes Care. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
8 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

10/29/2019

0 strong buy ratings
8 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

1/27/2020

0 strong buy ratings
9 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

4/26/2020

0 strong buy ratings
8 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

7/25/2020

0 strong buy ratings
9 buy ratings
5 hold ratings
0 sell ratings

Ratings as of

10/23/2020

0 strong buy ratings
9 buy ratings
5 hold ratings
0 sell ratings

Ratings as of

1/21/2021

0 strong buy ratings
9 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

3/22/2021

0 strong buy ratings
9 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

4/21/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price	Details
4/1/2021	SVB Leerink	Lower Price Target	Market Perform	$115.00 ➝ $95.00	Low	i
3/31/2021	Oppenheimer	Reiterated Rating	Buy		High	i
2/25/2021	Lake Street Capital	Boost Price Target	Buy	$137.00 ➝ $150.00	High	i
12/15/2020	Wells Fargo & Company	Downgrade	Overweight ➝ Equal Weight	$105.00	High	i
11/6/2020	Raymond James	Boost Price Target	Outperform	$116.00 ➝ $124.00	High	i
11/6/2020	SVB Leerink	Boost Price Target	Market Perform	$120.00 ➝ $130.00	High	i
11/6/2020	Piper Sandler	Boost Price Target	Overweight	$125.00 ➝ $132.00	High	i Rating by Matthew O'Brien at Piper Sandler
9/21/2020	Oppenheimer	Reiterated Rating	Buy	$120.00	High	i Rating by Steven Lichtman at Oppenheimer Holdings Inc.
8/28/2020	SVB Leerink	Boost Price Target	Market Perform	$115.00 ➝ $120.00	Low	i Rating by D. Antalffy at SVB Leerink LLC
8/20/2020	Wells Fargo & Company	Initiated Coverage	Overweight	$120.00	High	i
7/31/2020	Raymond James	Boost Price Target	Outperform	$95.00 ➝ $116.00	Low	i
7/31/2020	Craig Hallum	Boost Price Target	Buy	$102.00 ➝ $140.00	High	i Rating by Alexander Nowak at Craig Hallum
7/31/2020	Lake Street Capital	Boost Price Target	Positive ➝ Buy	$125.00 ➝ $137.00	High	i
7/31/2020	SVB Leerink	Boost Price Target	Market Perform	$105.00 ➝ $115.00	High	i Rating by D. Antalffy at SVB Leerink LLC
7/31/2020	Guggenheim	Upgrade	Neutral ➝ Buy	$130.00	High	i Rating by Christopher Pasquale at Guggenheim
7/31/2020	Piper Sandler	Boost Price Target	Overweight	$90.00 ➝ $125.00	High	i Rating by Matthew O'Brien at Piper Sandler
7/7/2020	Cowen	Boost Price Target	Positive ➝ Outperform	$85.00 ➝ $110.00	Low	i Rating by Ryan Blicker at Cowen Inc
7/6/2020	Citigroup	Upgrade	Neutral ➝ Buy	$94.00 ➝ $120.00	Low	i
6/30/2020	Oppenheimer	Initiated Coverage	Buy	$102.00	Low	i Rating by Steven Lichtman at Oppenheimer Holdings Inc.
6/30/2020	Piper Sandler	Reiterated Rating	Buy	$90.00	Low	i Rating by Matthew O'Brien at Piper Sandler
6/30/2020	Bank of America	Reiterated Rating	Hold	$100.00	Low	i Rating by Travis Steed at Bank of America Co.
6/30/2020	Cowen	Reiterated Rating	Buy	$85.00	Low	i Rating by Ryan Blicker at Cowen Inc
6/22/2020	UBS Group	Boost Price Target	Buy	$98.00 ➝ $106.00	Low	i
6/22/2020	Oppenheimer	Boost Price Target	Reduce ➝ Outperform	$92.00 ➝ $102.00	Low	i Rating by Steven Lichtman at Oppenheimer Holdings Inc.
6/18/2020	Lake Street Capital	Boost Price Target		$100.00 ➝ $125.00	Low	i
6/18/2020	Raymond James	Boost Price Target	Outperform	$88.00 ➝ $95.00	Low	i
6/17/2020	Oppenheimer	Initiated Coverage	Buy	$92.00	Low	i Rating by Steven Lichtman at Oppenheimer Holdings Inc.
6/3/2020	Citigroup	Boost Price Target	Average ➝ Neutral	$81.00 ➝ $94.00	Low	i
5/22/2020	Bank of America	Boost Price Target	Neutral	$85.00 ➝ $95.00	Low	i
5/1/2020	UBS Group	Lower Price Target	Buy	$100.00 ➝ $98.00	High	i
5/1/2020	Citigroup	Boost Price Target	Neutral	$74.00 ➝ $81.00	High	i
5/1/2020	Stifel Nicolaus	Boost Price Target	Hold	$65.00 ➝ $75.00	Medium	i
5/1/2020	Oppenheimer	Reiterated Rating	Buy	$92.00	High	i
5/1/2020	SVB Leerink	Boost Price Target	Market Perform	$85.00 ➝ $88.00	High	i Rating by D. Antalffy at SVB Leerink LLC
4/27/2020	Raymond James	Lower Price Target	Outperform	$91.00 ➝ $81.00	Low	i
4/24/2020	SVB Leerink	Downgrade	Outperform ➝ Market Perform		Low	i Rating by D. Antalffy at SVB Leerink LLC
4/20/2020	Craig Hallum	Lower Price Target	Buy	$108.00 ➝ $102.00	Medium	i Rating by Alexander Nowak at Craig Hallum
3/27/2020	Citigroup	Lower Price Target	Neutral	$89.00 ➝ $74.00	High	i
3/23/2020	Guggenheim	Downgrade	Buy ➝ Neutral		High	i
3/4/2020	Citigroup	Initiated Coverage	Neutral	$89.00	Medium	i
2/25/2020	Oppenheimer	Boost Price Target		$84.00 ➝ $97.00	High	i
2/25/2020	Piper Sandler	Boost Price Target	Overweight	$70.00 ➝ $90.00	High	i
2/25/2020	Craig Hallum	Boost Price Target	Buy	$92.00 ➝ $108.00	High	i Rating by Alexander Nowak at Craig Hallum
2/25/2020	Stifel Nicolaus	Boost Price Target	Hold	$70.00 ➝ $77.00	High	i
2/25/2020	Raymond James	Boost Price Target	Outperform	$85.00 ➝ $91.00	High	i
2/25/2020	Cowen	Reiterated Rating	Outperform	$85.00 ➝ $90.00	High	i
2/13/2020	Cowen	Boost Price Target	Outperform	$70.00 ➝ $85.00	Medium	i
2/12/2020	Craig Hallum	Reiterated Rating	Buy	$92.00	High	i Rating by Alexander Nowak at Craig Hallum
2/5/2020	Raymond James	Initiated Coverage	Outperform	$85.00	Low	i
2/4/2020	Robert W. Baird	Downgrade	Outperform ➝ Neutral	$71.00 ➝ $75.00	Low	i
12/13/2019	Craig Hallum	Reiterated Rating	Buy	$92.00	Low	i Rating by Alexander Nowak at Craig Hallum
10/17/2019	Guggenheim	Initiated Coverage	Buy	$76.00	Low	i
10/4/2019	UBS Group	Upgrade	Neutral ➝ Buy	$75.00	Low	i
8/2/2019	Oppenheimer	Boost Price Target		$80.00 ➝ $84.00	Medium	i
6/17/2019	Lake Street Capital	Reiterated Rating	Buy		Medium	i
5/17/2019	Bank of America	Reiterated Rating	Neutral	$65.00	Medium	i
5/13/2019	SVB Leerink	Initiated Coverage	Outperform ➝ Outperform	$83.00	Low	i Rating by D. Antalffy at SVB Leerink LLC
5/1/2019	Oppenheimer	Boost Price Target	Outperform	$68.00 ➝ $80.00	Medium	i Rating by Steven Lichtman at Oppenheimer Holdings Inc.
5/1/2019	Stifel Nicolaus	Boost Price Target	Hold ➝ Hold	$58.00 ➝ $70.00	Medium	i
5/1/2019	Craig Hallum	Reiterated Rating	Buy	$70.00 ➝ $84.00	High	i Rating by Alexander Nowak at Craig Hallum
4/30/2019	UBS Group	Boost Price Target	Neutral ➝ Neutral	$53.00 ➝ $66.00	High	i
3/8/2019	BMO Capital Markets	Initiated Coverage	Outperform ➝ Outperform	$77.00	High	i
3/5/2019	Bank of America	Boost Price Target	Neutral	$59.00 ➝ $65.00	Low	i
2/27/2019	Oppenheimer	Boost Price Target	Outperform	$57.00 ➝ $68.00	Medium	i Rating by Steven Lichtman at Oppenheimer Holdings Inc.
2/27/2019	Cowen	Boost Price Target	Outperform	$40.00 ➝ $60.00	Medium	i
2/27/2019	Craig Hallum	Boost Price Target	Buy	$59.00 ➝ $70.00	Medium	i Rating by Alexander Nowak at Craig Hallum
2/27/2019	Lake Street Capital	Boost Price Target	Buy ➝ Buy	$60.00 ➝ $100.00	High	i Rating by Brooks O'Neil at Lake Street Capital
2/27/2019	Piper Jaffray Companies	Upgrade	Overweight	$67.00	High	i
2/15/2019	Robert W. Baird	Boost Price Target	Outperform	$46.00 ➝ $55.00	Medium	i
11/27/2018	UBS Group	Initiated Coverage	Neutral	$36.00	High	i
11/21/2018	Robert W. Baird	Upgrade	Neutral ➝ Outperform	$46.00	High	i
11/9/2018	Oppenheimer	Set Price Target	Buy	$57.00	Medium	i Rating by Steven Lichtman at Oppenheimer Holdings Inc.
11/3/2018	Lake Street Capital	Set Price Target	Buy	$60.00	High	i Rating by Brooks O'Neil at Lake Street Capital
11/2/2018	Craig Hallum	Set Price Target	Buy	$59.00	High	i Rating by Alexander Nowak at Craig Hallum
11/2/2018	Oppenheimer	Set Price Target	Buy	$57.00	High	i Rating by Steven Lichtman at Oppenheimer Holdings Inc.
10/15/2018	Lake Street Capital	Set Price Target	Buy	$60.00	High	i Rating by Brooks O'Neil at Lake Street Capital
9/26/2018	Dougherty & Co	Boost Price Target	Buy	$45.00 ➝ $56.00	Low	i
9/26/2018	Piper Jaffray Companies	Reiterated Rating	Above Average ➝ Overweight	$32.00 ➝ $56.00	Medium	i
9/25/2018	Oppenheimer	Reiterated Rating	Buy	$57.00	Low	i Rating by Steven Lichtman at Oppenheimer Holdings Inc.
9/20/2018	Craig Hallum	Initiated Coverage	Buy	$52.00 ➝ $52.00	Low	i
9/14/2018	Robert W. Baird	Downgrade	Outperform ➝ Neutral		Medium	i
9/5/2018	Oppenheimer	Set Price Target	Buy	$54.00	High	i Rating by Steven Lichtman at Oppenheimer Holdings Inc.
8/30/2018	Berenberg Bank	Initiated Coverage	Buy ➝ Buy	$50.00	High	i
8/24/2018	Dougherty & Co	Initiated Coverage	Buy ➝ Buy	$45.00	High	i
8/24/2018	Bank of America	Upgrade	Underperform ➝ Neutral	$45.00	High	i
8/22/2018	Stifel Nicolaus	Initiated Coverage	Hold	$25.00 ➝ $34.00	High	i
8/20/2018	Lake Street Capital	Boost Price Target	Buy	$35.00 ➝ $65.00	Low	i
8/6/2018	Oppenheimer	Set Price Target	Buy	$31.00 ➝ $38.00	High	i Rating by Steven Lichtman at Oppenheimer Holdings Inc.
7/31/2018	Oppenheimer	Set Price Target	Buy	$31.00	High	i Rating by Steven Lichtman at Oppenheimer Holdings Inc.
7/31/2018	Lake Street Capital	Boost Price Target	Buy	$35.00	High	i
7/31/2018	Piper Jaffray Companies	Boost Price Target	Overweight	$32.00	High	i
7/31/2018	Stifel Nicolaus	Reiterated Rating	Hold ➝ Hold	$7.50 ➝ $25.00	High	i
7/31/2018	Cowen	Reiterated Rating	Buy	$28.00	High	i
7/23/2018	Robert W. Baird	Reiterated Rating	Buy	$31.00	High	i
6/22/2018	Piper Jaffray Companies	Upgrade	Overweight	$25.00	High	i
6/18/2018	Lake Street Capital	Initiated Coverage	Buy	$30.00	High	i
5/27/2018	Oppenheimer	Set Price Target	Buy	$15.00	High	i Rating by Steven Lichtman at Oppenheimer Holdings Inc.
5/21/2018	Oppenheimer	Set Price Target	Buy	$10.00 ➝ $15.00	High	i Rating by Steven Lichtman at Oppenheimer Holdings Inc.
5/14/2018	Piper Jaffray Companies	Upgrade	Neutral ➝ Overweight		High	i
4/6/2018	Oppenheimer	Set Price Target	Buy	$8.00	High	i Rating by Steven Lichtman at Oppenheimer Holdings Inc.
3/28/2018	Cowen	Upgrade	Market Perform ➝ Outperform		Medium	i
3/23/2018	Robert W. Baird	Upgrade	Neutral ➝ Outperform		High	i
3/22/2018	Oppenheimer	Reiterated Rating	Buy		Medium	i Rating by Steven Lichtman at Oppenheimer Holdings Inc.
3/2/2018	Stifel Nicolaus	Reiterated Rating	Hold	$4.00	High	i
2/27/2018	Cowen	Reiterated Rating	Hold		Medium	i
2/27/2018	Citigroup	Initiated Coverage	Outperform	$5.50	Low	i
2/26/2018	Oppenheimer	Initiated Coverage	Buy	$5.50 ➝ $6.00	High	i Rating by Steven Lichtman at Oppenheimer Holdings Inc.
11/19/2017	Robert W. Baird	Reiterated Rating	Hold	$3.00	N/A	i
10/10/2017	Wedbush	Reiterated Rating	Outperform	$50.00 ➝ $17.00	N/A	i
10/6/2017	Piper Jaffray Companies	Reiterated Rating	Hold	$15.00	N/A	i
5/3/2017	B. Riley	Reiterated Rating	Neutral	$15.00	Medium	i Rating by G. Chodaczek at B. Riley
4/28/2017	B. Riley	Reiterated Rating	Neutral	$15.00	Low	i Rating by G. Chodaczek at B. Riley
4/10/2017	Cowen	Downgrade	Outperform ➝ Market Perform	$15.00	Medium	i
3/30/2017	Wedbush	Reiterated Rating	Outperform	$110.00	Low	i
3/30/2017	Piper Jaffray Companies	Reiterated Rating	Neutral ➝ Neutral		Medium	i
3/29/2017	B. Riley	Downgrade	Neutral	$15.00	Medium	i Rating by G. Chodaczek at B. Riley
3/24/2017	B. Riley	Downgrade	Buy ➝ Neutral	$50.00 ➝ $15.00	Low	i Rating by G. Chodaczek at B. Riley
3/11/2017	B. Riley	Reiterated Rating	Buy	$50.00	N/A	i
3/9/2017	Northcoast Research	Reiterated Rating	Buy		N/A	i Rating by E. Snyder at Northcoast Research
1/24/2017	Wedbush	Reiterated Rating	Positive		N/A	i
11/7/2016	B. Riley	Reiterated Rating	Buy	$70.00	N/A	i
11/3/2016	Piper Jaffray Companies	Downgrade	Overweight ➝ Neutral		N/A	i
11/2/2016	B. Riley	Reiterated Rating	Buy	$70.00	N/A	i
11/2/2016	Deutsche Bank Aktiengesellschaft	Lower Price Target	Buy	$140.00 ➝ $90.00	N/A	i
11/2/2016	Feltl & Co.	Downgrade	Strong-Buy ➝ Buy		N/A	i Rating by B. Haynor at Feltl & Co.
11/2/2016	Wedbush	Lower Price Target	Outperform	$200.00 ➝ $110.00	N/A	i
11/2/2016	Robert W. Baird	Downgrade	Outperform ➝ Neutral	$110.00 ➝ $40.00	N/A	i
11/2/2016	Stifel Nicolaus	Downgrade	Buy ➝ Hold	$150.00 ➝ $35.00	N/A	i
10/2/2016	B. Riley	Initiated Coverage	Buy	$100.00	N/A	i
9/26/2016	B. Riley	Initiated Coverage	Buy	$100.00	N/A	i Rating by G. Chodaczek at B. Riley
7/29/2016	Wedbush	Reiterated Rating	Outperform	$200.00	N/A	i
6/15/2016	Wedbush	Reiterated Rating	Outperform	$200.00	N/A	i
5/16/2016	Sterne Agee CRT	Reiterated Rating	Neutral		N/A	i Rating by G. Chodaczek at Sterne Agee CRT
5/2/2016	Robert W. Baird	Reiterated Rating	Buy		N/A	i
4/21/2016	Piper Jaffray Companies	Reiterated Rating	Buy	$120.00	N/A	i Rating by Brooks West at Piper Jaffray Companies

(Data available from 4/21/2016 forward)

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin with Basal-IQ and control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump's software. In addition, the company offers t:connect, a web-based data management application, which provides a visual way to display diabetes therapy management data from the pump, continuous glucose monitoring, and supported blood glucose meters for users, their caregivers, and their healthcare providers; and Sugarmate, a mobile app for people with diabetes who use insulin. Its products in development include t:sport insulin delivery system; and connected (mobile) health offerings. Tandem Diabetes Care, Inc. has a development and commercialization agreement with Dexcom, Inc. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.

Today's Range

Now: $92.92

$90.67

$93.08

50 Day Range

MA: $87.78

$81.28

$95.83

52 Week Range

Now: $92.92

$68.00

$123.74

Volume

550,791 shs

Average Volume

774,395 shs

Market Capitalization

$5.81 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.31

Frequently Asked Questions

What sell-side analysts currently cover shares of Tandem Diabetes Care?

The following Wall Street research analysts have issued stock ratings on Tandem Diabetes Care in the last year: Bank of America Co., Citigroup Inc., Cowen Inc, Craig Hallum, Guggenheim, Lake Street Capital, Oppenheimer Holdings Inc., Piper Sandler, Raymond James, Stifel Nicolaus, SVB Leerink LLC, UBS Group AG, Wells Fargo & Company, and Zacks Investment Research.
View the latest analyst ratings for TNDM.

What is the current price target for Tandem Diabetes Care?

13 Wall Street analysts have set twelve-month price targets for Tandem Diabetes Care in the last year. Their average twelve-month price target is $115.92, suggesting a possible upside of 24.8%. Lake Street Capital has the highest price target set, predicting TNDM will reach $150.00 in the next twelve months. Stifel Nicolaus has the lowest price target set, forecasting a price of $75.00 for Tandem Diabetes Care in the next year.
View the latest price targets for TNDM.

What is the current consensus analyst rating for Tandem Diabetes Care?

Tandem Diabetes Care currently has 4 hold ratings and 9 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe TNDM will outperform the market and that investors should add to their positions of Tandem Diabetes Care.
View the latest ratings for TNDM.

What other companies compete with Tandem Diabetes Care?

Other companies that are similar to Tandem Diabetes Care include Teleflex, NovoCure, Insulet, Abiomed, Penumbra, Hill-Rom, Globus Medical, Integra LifeSciences, Inspire Medical Systems, Nevro, Inari Medical, ShockWave Medical, ICU Medical, Glaukos and Cantel Medical.

How do I contact Tandem Diabetes Care's investor relations team?

Tandem Diabetes Care's physical mailing address is 11075 ROSELLE STREET, San Diego CA, 92121. The medical device company's listed phone number is 858-366-6900 and its investor relations email address is [email protected] The official website for Tandem Diabetes Care is www.tandemdiabetes.com.

NASDAQ:TNDM - Tandem Diabetes Care Stock Price Target and Predictions

Analyst Price Target for TNDM

Past Monthly Recommendations

Latest Recommendations

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Tandem Diabetes Care?

What is the current price target for Tandem Diabetes Care?

What is the current consensus analyst rating for Tandem Diabetes Care?

What other companies compete with Tandem Diabetes Care?

How do I contact Tandem Diabetes Care's investor relations team?